FIELD: biochemistry; cell biology; immunotherapy.
SUBSTANCE: following has been proposed: genome-edited chimeric antigen receptor T-cells (CAR-T) which can be derived from cytotoxic T-cells, virus-specific cytotoxic T-cells, memory T-cells, or gamma delta (γδ) T-cells and contain one or more chimeric antigen receptors (CARs) targeting one or more antigens, wherein the CAR-T-cell is deficient in one or more antigens to which one or more CARs specifically bind. In particular, the invention relates to engineered T-cells (CAR-T) bearing mono, dual and tandem chimeric antigen receptors (CARs) and immunotherapy methods of the treatment of cancer.
EFFECT: invention provides CAR-T-cells for more efficient, safe and effective targeting of cancer.
16 cl, 13 dwg, 27 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
| FULLY HUMAN MESOTHELIN ANTIBODIES AND IMMUNE EFFECTOR CELLS TARGETING MESOTHELIN | 2016 |
|
RU2748281C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING CD70 | 2019 |
|
RU2801824C2 |
| CHIMERIC ANTIGEN RECEPTOR (CAR) WITH ANTIGEN-BINDING DOMAINS TO THE T-CELL RECEPTOR β- CONSTANT REGION | 2015 |
|
RU2744046C2 |
| ANTI-HLA-A2 ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2782276C2 |
| T-CELLS MODIFIED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING CS1 | 2015 |
|
RU2727451C2 |
| GLYPICAN-3 ANTIBODY AND USE THEREOF | 2016 |
|
RU2744245C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| T-CELLS MODIFIED WITH CHIMERIC ANTIGEN RECEPTOR TARGETED TO CS1 FOR TREATMENT OF AMYLOIDOSIS AL | 2018 |
|
RU2774895C2 |
